APA (7th ed.) Citation

KH, L., YH, W., YH, C., SC, C., CB, L., & SH, L. (2026). The prognostic value of 18F-FDG PET-derived whole-body feature in patients with lung adenocarcinoma treated with EGFR-targeted therapy. Annals of nuclear medicine, 40(2), 121. https://doi.org/10.1007/s12149-025-02108-6

Chicago Style (17th ed.) Citation

KH, Lue, Wang YH, Chen YH, Chu SC, Lin CB, and Liu SH. "The Prognostic Value of 18F-FDG PET-derived Whole-body Feature in Patients with Lung Adenocarcinoma Treated with EGFR-targeted Therapy." Annals of Nuclear Medicine 40, no. 2 (2026): 121. https://doi.org/10.1007/s12149-025-02108-6.

MLA (9th ed.) Citation

KH, Lue, et al. "The Prognostic Value of 18F-FDG PET-derived Whole-body Feature in Patients with Lung Adenocarcinoma Treated with EGFR-targeted Therapy." Annals of Nuclear Medicine, vol. 40, no. 2, 2026, p. 121, https://doi.org/10.1007/s12149-025-02108-6.